Adjuvanted Virosome Membrane Integration via Post-Formation Dilution
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for preparing virosome-based vaccines with incorporated adjuvants face challenges in determining the optimal antigen/adjuvant ratio, leading to increased costs and potential side effects due to fixed adjuvant incorporation during virosome formation, which limits flexibility in clinical testing and patient responses.
Innovation Solution
A two-step method where virosomes are pre-formed without adjuvants, and amphiphilic adjuvants are added post-formation by dissolving them in a suitable solvent, allowing integration into the outer leaflet of the virosomal membrane, enabling variable adjuvant/antigen ratios and reduced adjuvant concentration to minimize side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If adjuvants are incorporated during virosome formation, then the adjuvant is integrated into the virosomal membrane, but the adjuvant/antigen ratio is fixed and cannot be adjusted for different clinical needs
Solution Approach 1:
The patent divides the adjuvant incorporation process into separate steps: first forming virosomes with antigens, then separately adding adjuvants in controlled amounts. This segmentation allows independent adjustment of adjuvant/antigen ratios without reformatting the entire virosome production process, resolving the contradiction between adaptability and process complexity.
Solution Approach 2:
The patent performs preliminary action by pre-forming virosomes with antigens before adding adjuvants. This allows the virosomal structure to be established first, then enables flexible addition of varying adjuvant amounts afterward, achieving ratio adjustability without complicating the core virosome formation process.
2Reliability
If higher adjuvant concentration is used, then immune response is enhanced, but side effects increase
Solution Approach 1:
The patent implements dynamic adjustment of adjuvant concentration based on specific clinical requirements. By separating adjuvant addition from virosome formation, the system allows optimization of adjuvant levels to achieve sufficient immune response while minimizing side effects, resolving the contradiction between efficacy and safety.
3Ease of operation
If adjuvant is incorporated during virosome formation, then adjuvant is distributed throughout the membrane, but adjuvant cannot be selectively placed in the outer leaflet for optimal immune interaction
Solution Approach 1:
The patent extracts the adjuvant incorporation step from the virosome formation process. By adding adjuvants separately after virosomes are formed, the method enables selective placement of adjuvants in the outer leaflet of the membrane where they can optimally interact with the immune system, rather than being distributed throughout the entire membrane structure.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach simplifies preclinical and clinical testing, reduces adjuvant usage, and maintains immunogenicity while minimizing side effects by ensuring only the outer leaflet adjuvant interacts with the immune system, thus enhancing vaccine efficacy and safety.
Implementation Method 1
amphiphilic adjuvants are added post-formation by dissolving them in a suitable solvent, allowing integration into the outer leaflet of the virosomal membrane
Implementation Method 2
non-aqueous adjuvant solvent has a solubility in water of at least 5 g/100 mL at 20°C; diluting said adjuvant solution in said aqueous virosome composition
Data Source
Figure 1A
Figure 1B
Figure 2
AI summary
The invention relates to the fields of immunology and vaccinology. Provided is a method for preparing adjuvanted virosomes, comprising the steps of: (i) providing an aqueous composition of non-adjuvanted virosomes comprising a membrane fusion protein; (ii) dissolving an amphiphilic adjuvant in a pharmaceutically acceptable non-aqueous solvent which can form a homogeneous mixture with water; and (iii) diluting said adjuvant solution in said aqueous virosome composition to induce insertion of adjuvant in the outer leaflet of the virosomal membrane while preserving membrane fusion activity of the virosomes. Also provided are adjuvanted virosomes obtainable by said method, and vaccines comprising the virosomes.